Citigroup Reiterates Buy Rating, $31 PT on Ariad Pharmaceuticals
In a report published Friday, Citigroup reiterated its Buy rating and $31.00 price target on Ariad Pharmaceuticals (NASDAQ: ARIA).
Citigroup noted, “Today's announcement of the over 3 month early decision for the approval of Iclusig (ponatinib) in CML is a positive surprise, but the inclusion of a black box warning on the label was not in consensus expectation, in our view. We note that Tasigna has a black box warning and Sprycel, while no black box warning, has many warnings including pleural infusions (accumulation of fluid around the lungs).”
Ariad Pharmaceuticals closed on Thursday at $23.88.
Latest Ratings for ARIA
|Oct 2016||SunTrust Robinson Humphrey||Initiates Coverage on||Buy|
|Sep 2016||Leerink Swann||Initiates Coverage on||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.